Last reviewed · How we verify
Vancomycin (or equivalent)
Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.
Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors. Used for Treatment of acute bacterial skin and skin structure infections (ABSSSI), Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), Treatment of severe or life-threatening infections caused by susceptible Gram-positive bacteria.
At a glance
| Generic name | Vancomycin (or equivalent) |
|---|---|
| Sponsor | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Drug class | glycopeptide antibiotic |
| Target | D-alanyl-D-alanine terminus of cell wall precursors |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
This prevents the incorporation of these precursors into the bacterial cell wall, ultimately leading to cell lysis and death. Vancomycin is a glycopeptide antibiotic that is effective against a wide range of Gram-positive pathogens.
Approved indications
- Treatment of acute bacterial skin and skin structure infections (ABSSSI)
- Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)
- Treatment of severe or life-threatening infections caused by susceptible Gram-positive bacteria
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Headache
- Rash
- Hypersensitivity reactions
- Anaphylaxis
Key clinical trials
- Combination Study of Antibiotics With Enzalutamide (PROMIZE) (PHASE1, PHASE2)
- Oral Vancomycin for Preventing Clostridium Difficile Recurrence (PHASE4)
- Study of Debio 1450 for Bacterial Skin Infections (PHASE2)
- Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006) (PHASE3)
- Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: